ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Development and Validation of a Blood-Biomarker-Based Predictive Model for HBV-Associated Hepatocellular Carcinoma.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to explore the optimal predictors of HBV-associated HCC using Lasso, and establish a prediction model.
methodsA retrospective analysis was conducted on patients who underwent CBC and CRP testing between January 2016 and March 2024. The study population comprised 5441 cases divided into three cohorts: non-HBV-infected (1333 cases), HBV-infected (1023 cases), and HBV-associated HCC (3085 cases). A value of CRP <10 mg/L was used to exclude cases of acute bacterial infections. Baseline data and blood parameters were compared across the three groups (control group (n = 1049), the HBV-infected group (n = 789), and the HBV-associated HCC group (n = 1367)). HBV-infected group and the HBV-associated HCC group were used as modeling subjects which 70% were classified as training set (n = 1512) and 30% were classified as validation set (n = 644). Lasso regression and logistic regression were employed to identify the most effective predictors of HBV-associated HCC, which were subsequently incorporated into a predictive model by training set.
resultsSignificant variations in age, gender, and blood parameter indices were observed between individuals with acute bacterial infections and non-infections in the study population, and also between three groups. The optimal predictors identified for HBV-associated HCC included gender, age, MONO, EO%, MCHC, MPV, and PCT.
conclusionsThe study highlights the significant impact of acute bacterial infections on immune status, erythrocyte system, and platelet system. After excluding acute bacterial infections, factors such as gender, age, MONO, EO%, MCHC, MPV, and PCT are effective predictors for clinical prediction of HCC development in HBV-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.